| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| LISATA THERAPEUTICS, INC. | EVP, R&D and CMO | Common Stock | 54K | $162K | $2.99 | Jan 10, 2024 | Direct |
| LISATA THERAPEUTICS, INC. | EVP, R&D and CMO | Stock Option (Right to Buy) | 14K | Jan 9, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| LSTA | LISATA THERAPEUTICS, INC. | Jan 9, 2024 | 5 | -$18.1K | 4 | Jan 11, 2024 | EVP, R&D and CMO |
| LSTA | LISATA THERAPEUTICS, INC. | Sep 1, 2023 | 1 | -$6.34K | 4 | Sep 5, 2023 | EVP, R&D and CMO |
| LSTA | LISATA THERAPEUTICS, INC. | Jan 9, 2023 | 4 | -$8.08K | 4 | Jan 11, 2023 | EVP, R&D and CMO |
| LSTA | CALADRIUS BIOSCIENCES, INC. | Sep 1, 2022 | 3 | -$5.98K | 4 | Sep 2, 2022 | EVP, R&D and CMO |
| LSTA | CALADRIUS BIOSCIENCES, INC. | Jan 10, 2022 | 3 | -$7.06K | 4 | Jan 12, 2022 | EVP, R&D and CMO |
| LSTA | CALADRIUS BIOSCIENCES, INC. | Sep 1, 2021 | 3 | -$64.1K | 4 | Sep 3, 2021 | EVP, R&D and CMO |
| LSTA | CALADRIUS BIOSCIENCES, INC. | Sep 1, 2021 | 0 | $0 | 3 | Sep 3, 2021 | EVP, R&D and CMO |